Startups developing a solution for the treatment of mitral regurgitation, a crypto accounting software, AI to improve the healthcare system,s treamlined literature review, and illumination for optogenetics each get CHF 10,000
29.08.2024
Adjust Medical, Breezing, Intonate, LiteRev, OptoLumina were selected at Venture Kick's first financial and entrepreneurial support stage. Their projects develop a minimalist simple solution for the treatment of mitral regurgitation; help crypto accountants and crypto business clients to do their accounting & tax; enable the data protection-compliant recording of consultations between doctors and their patients; offer an innovative end-to-end solution for efficient and reliable document reviews; and provide a groundbreaking technology that holds the potential to significantly enhance biotechnology yields, streamline drug screening processes, and even restore vision.
 |
 |
 Adjust Medical: Co-Founders Youssef Biadillah, Vitali Verin, Giovanni Leo, and Aristotelis Panos
|
|
 Breezing: Co-Founders Selem Essaied and Bassil Eid
|
|
 Intonate: COO Tim Gmünder, CEO Julian Sutter, and CTO Livio Schlaepfer
|
|
 LiteRev: Dr. Aziza Merzouki, Prof. Olivia Keiser, and Dr. Erol Orel
|
|
 OptoLumina: Engineer Christoph Papailiou, CEO Thomas Höhener, and CTO Alex Landolt
|
|
Adjust Medical: Minimalist Simple Solution for the treatment of Mitral Regurgitation
Primary mitral regurgitation (MR) is the most common heart valve pathology affecting 2% of the general population and is associated with decreased mid- and long-term survival rates. In the US alone, 2 million patients suffer from MR and that number is expected to double by 2030. Few minimally invasive, catheter-based solutions, exist but they suffer from various limitations including procedural complexity, large bulky implants, and the inability to subsequently treat patients with other devices.
Adjust Medical has developed the AdjusTer™: A small, form-factor, device that aims to become the world's smallest MR implant to safely and effectively treat MR via a minimally invasive out-patient procedure without eliminating subsequent treatment options. The company was founded by Dr. Vitali Verin, an interventional cardiologist at Clinique de Genolier, Vaud, Dr
Aristotelis Panos, mitral valve surgeon at Hôpital de La Tour, Geneva, Mr. Giovanni Leo, a medical device executive with 30 years of experience, and Mr. Youssef Biadillah, a medical device executive with 20 years of experience.
The Venture Kick funds will help the company move from in-vitro to in-vivo pre-clinical testing.
Breezing: crypto accounting software
Intonate: Responsibly leveraging AI to improve the healthcare system.
The excessive documentation burden on doctors today leads to decreased job satisfaction and burnout, negatively impacting patient care.
Intonate enables the data protection-compliant recording of consultations between doctors and their patients, including those in Swiss German. Based on the relevant information provided in the recording, the AI-powered technology automatically generates a structured medical report suggestion within seconds. The global size of the market is estimated at CHF 15.5 billion, with the Swiss market estimated at CHF 500 million. The startup primarily focuses on the outpatient sector, and its software is already being used in several general practices and by specialists. Intonate's founding team is highly diverse, comprising a doctor and two graduates from ETH Zürich - one with a Master's in Computer Science and the other with a Master's in MTEC.
The Venture Kick fund will contribute to a pilot project that assesses the technology’s precision in processing different Swiss German dialects.
LiteRev: Streamlining literature review
The explosion of publications across various domains has created overwhelming challenges to review and stay up-to-date with new information. Existing AI-powered tools offer partial solutions but fall short in providing a comprehensive and unbiased review process.
Founded by a multidisciplinary team of experts, including Prof. Olivia Keiser, Dr. Aziza Merzouki, and Dr. Erol Orel, LiteRev offers an innovative end-to-end solution for efficient and reliable document reviews. By combining advanced AI-driven algorithms with a user-friendly interface, LiteRev serves researchers, policymakers, and professionals across various sectors. LiteRev has already gained traction with leading academic, healthcare, and legal institutions. With a serviceable addressable market for evidence review software estimated at around 2 billion USD and expected to grow significantly, LiteRev is well-positioned to make a substantial impact.
LiteRev will use the Venture Kick Stage 1 funds to develop marketing and partnership initiatives and accelerate prototype development. This will support the successful market entry of LiteRev and position it as the leading solution for automated, comprehensive evidence reviews across diverse sectors.
OptoLumina: Innovating Industrial-Grade Illumination for Optogenetics
OptoLumina is developing the Lumiplate an advanced well plate illumination device designed for industrial optogenetics applications.
Optogenetics is a groundbreaking technology that holds the potential to significantly enhance biotechnology yields, streamline drug screening processes, and even restore vision. The Lumiplate is engineered to address the lack of illumination devices that hinder the adoption of this technology in industrial settings.
Leveraging the success of a pilot project and insights from industry experts, the founding team — consisting of a PhD graduate with deep expertise in optogenetics, an electrical engineer, and a CAD engineer — is driving the development of the Lumiplate. The market potential for optogenetics is immense, with projections for 2030 ranging from 1 billion to over 30 billion USD.
The Venture Kick Stage 1 funds will be instrumental in acquiring prototypes for collaborations, which will provide invaluable feedback, and help promote OptoLumina in the market.
Primary mitral regurgitation (MR) is the most common heart valve pathology affecting 2% of the general population and is associated with decreased mid- and long-term survival rates. In the US alone, 2 million patients suffer from MR and that number is expected to double by 2030. Few minimally invasive, catheter-based solutions, exist but they suffer from various limitations including procedural complexity, large bulky implants, and the inability to subsequently treat patients with other devices.
Adjust Medical has developed the AdjusTer™: A small, form-factor, device that aims to become the world's smallest MR implant to safely and effectively treat MR via a minimally invasive out-patient procedure without eliminating subsequent treatment options. The company was founded by Dr. Vitali Verin, an interventional cardiologist at Clinique de Genolier, Vaud, Dr
Aristotelis Panos, mitral valve surgeon at Hôpital de La Tour, Geneva, Mr. Giovanni Leo, a medical device executive with 30 years of experience, and Mr. Youssef Biadillah, a medical device executive with 20 years of experience.
The Venture Kick funds will help the company move from in-vitro to in-vivo pre-clinical testing.
Breezing: crypto accounting software
Currently, accountants use excel to manage accounting for crypto transactions. Breezing is a crypto accounting software that pulls transactions from the blockchain (BTC, ETH, etc), convert to FIAT (CHF, USD, etc) and pushes a journal entry into your accounting system (Xero, Bexio, Quickbooks, etc). Our product is for crypto accountants and crypto business clients who use crypto in their day-to-day business and need a solution to do their accounting & tax.
Breezing is founded by Bassil Eid, CEO & Selem Essaied, CTO and works closely with Zurich University of Applied sciences. The product already has over +30 institutional clients having been operating less than 12 months. The estimated service addressable market of 2 billion USD.
Breezing will use Venture Kick Stage 1 funds to develop the next generation of its product moving past the MVP stage into a more robust enterprise solution.
Breezing will use Venture Kick Stage 1 funds to develop the next generation of its product moving past the MVP stage into a more robust enterprise solution.
Intonate: Responsibly leveraging AI to improve the healthcare system.
The excessive documentation burden on doctors today leads to decreased job satisfaction and burnout, negatively impacting patient care.
Intonate enables the data protection-compliant recording of consultations between doctors and their patients, including those in Swiss German. Based on the relevant information provided in the recording, the AI-powered technology automatically generates a structured medical report suggestion within seconds. The global size of the market is estimated at CHF 15.5 billion, with the Swiss market estimated at CHF 500 million. The startup primarily focuses on the outpatient sector, and its software is already being used in several general practices and by specialists. Intonate's founding team is highly diverse, comprising a doctor and two graduates from ETH Zürich - one with a Master's in Computer Science and the other with a Master's in MTEC.
The Venture Kick fund will contribute to a pilot project that assesses the technology’s precision in processing different Swiss German dialects.
LiteRev: Streamlining literature review
The explosion of publications across various domains has created overwhelming challenges to review and stay up-to-date with new information. Existing AI-powered tools offer partial solutions but fall short in providing a comprehensive and unbiased review process.
Founded by a multidisciplinary team of experts, including Prof. Olivia Keiser, Dr. Aziza Merzouki, and Dr. Erol Orel, LiteRev offers an innovative end-to-end solution for efficient and reliable document reviews. By combining advanced AI-driven algorithms with a user-friendly interface, LiteRev serves researchers, policymakers, and professionals across various sectors. LiteRev has already gained traction with leading academic, healthcare, and legal institutions. With a serviceable addressable market for evidence review software estimated at around 2 billion USD and expected to grow significantly, LiteRev is well-positioned to make a substantial impact.
LiteRev will use the Venture Kick Stage 1 funds to develop marketing and partnership initiatives and accelerate prototype development. This will support the successful market entry of LiteRev and position it as the leading solution for automated, comprehensive evidence reviews across diverse sectors.
OptoLumina: Innovating Industrial-Grade Illumination for Optogenetics
OptoLumina is developing the Lumiplate an advanced well plate illumination device designed for industrial optogenetics applications.
Optogenetics is a groundbreaking technology that holds the potential to significantly enhance biotechnology yields, streamline drug screening processes, and even restore vision. The Lumiplate is engineered to address the lack of illumination devices that hinder the adoption of this technology in industrial settings.
Leveraging the success of a pilot project and insights from industry experts, the founding team — consisting of a PhD graduate with deep expertise in optogenetics, an electrical engineer, and a CAD engineer — is driving the development of the Lumiplate. The market potential for optogenetics is immense, with projections for 2030 ranging from 1 billion to over 30 billion USD.
The Venture Kick Stage 1 funds will be instrumental in acquiring prototypes for collaborations, which will provide invaluable feedback, and help promote OptoLumina in the market.